Reference health
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy
25/25 checkable references clean · checked 2026-08-10
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 25 checked references that resolve
resolves10.1186/s12882-018-0989-z
Increased risk of deep vein thrombosis in end-stage renal disease patients
resolves10.1371/journal.pone.0212237
Evaluation of hemostasis in patients with end-stage renal disease
resolves10.1002/phar.1905
Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
resolves10.1002/rth2.12083
Safety and effectiveness of apixaban compared to warfarin in dialysis patients
resolves10.1159/000445328
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis
resolves10.1681/ASN.2009030319
Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation
resolves10.1136/openhrt-2016-000441
Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis
resolves10.1161/CIRCULATIONAHA.118.035418
Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States
resolves10.1161/CIR.0000000000000665
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
resolves10.1161/CIRCULATIONAHA.114.014113
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
resolves10.1111/j.1538-7836.2005.01204.x
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
resolves10.1055/s-0041-1740254
Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
resolves10.1182/bloodadvances.2019000972
Outcomes associated with apixaban vs warfarin in patients with renal dysfunction
resolves10.1177/1060028018781853
Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease
resolves10.1177/1060028017694654
Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease
resolves10.1111/bcp.12114
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
resolves10.1177/1060028017717282
A Multicenter Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis
resolves10.1016/j.thromres.2020.09.002
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
resolves10.1093/ajhp/zxz013
Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion
The 3 references without a DOI — listed, not checked
no DOI — not checkedClayville LR, Anderson KV, Miller SA, St. Onge EL (2011) New options in anticoagulation for the prevention of venous thromboembolism and stroke. Pharm Ther 36:86–99
no DOI — not checkedEliquis [package insert]. Princeton: Bristol-Myers Squibb Company, 2014. https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 14 April 2022
no DOI — not checkedXarelto [package insert]. Titusville: Janssen Pharmaceuticals, Inc., 2020. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf. Accessed 14 April 2022
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-10 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s11239-022-02650-4"><img src="https://citestamp.com/citestamped/10.1007/s11239-022-02650-4/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s11239-022-02650-4)